As of Jan 17
| -0.30 / -4.80%|
The 6 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +34.45% increase from the last price of 5.95.
The current consensus among 8 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.